Antiproteinuric effect of valsartan, lisinopril and valsartan plus lisinopril in non-diabetic and diabetic renal disease: a randomized, double-blind, parallel group controlled trial with 5 months follow-up.
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lisinopril (Primary) ; Valsartan (Primary)
- Indications Hypertension; Proteinuria
- Focus Pharmacodynamics
- 07 Nov 2011 Actual end date (July 2006) added as reported by ClinicalTrials.gov.
- 09 Jan 2007 Status change
- 14 Nov 2005 New trial record.